Halozyme Therapeutics (HALO) announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals (ABOS) that provides Acumen access to Halozyme’s ENHANZE drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme for rapid subcutaneous drug delivery, for a single target. Acumen intends to explore the potential use of ENHANZE for ACU193, Acumen’s clinical-stage monoclonal antibody candidate to target Amyloid-beta Oligomers for the treatment of early Alzheimer’s disease. Under the terms of the agreement, Acumen will make an upfront payment to Halozyme, and potential future milestone payments related to development progress, regulatory approvals, and sales attainment. Halozyme will also be entitled to single digit royalties on net sales of commercialized medicines with the ENHANZE technology.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HALO:
- HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
- HALO Upcoming Earnings Report: What to Expect?
- Halozyme confirms ‘positive’ results from Bristol Myers’ Phase 3 CheckMate-67T
- Bristol Myers reports results from Phase 3 CheckMate -67T trial
- Halozyme price target raised to $61 from $60 at H.C. Wainwright
